COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Grows Operations in Arizona
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds Real Estate and Operations in Texas
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
TSC Life Receives FDA Clearance for Pediatric Use with Fluido® Compact System, a Blood & Fluid Warmer, in the U.S. and Canada
03/02/2026
DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- TSC Life , a global medtech company redefining healthcare with high-performance devices for temperature management and endoscopy, announced today that the U.S. Food and Drug [...]
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
03/02/2026
LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans [...]
The Ensign Group Buys Real Estate and Operations in Wisconsin
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
03/02/2026
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
03/02/2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
03/02/2026
FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
62,752 Orion Corporation A shares converted into B shares
03/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 FEBRUARY 2026 at 9.00 EET 62,752 Orion Corporation A shares converted into B shares In accordance with [...]
Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine
03/02/2026
First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with [...]
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
03/02/2026
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and [...]
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones
03/02/2026
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off- [...]
Zelluna promotes Emilie Gauthy to Chief Technology Officer
03/02/2026
Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced the [...]
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros
03/02/2026
Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros Paris, 3 février 2026. Le 29 janvier 2026, Sanofi a annoncé son intention d’exécuter un programme de rachat d' [...]
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
03/02/2026
Lyon (France), Sao Paulo, (Brazil), February 3, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today [...]
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
03/02/2026
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone ( [...]
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
03/02/2026
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company [...]
Natures Aid Introduces NSF-Certified Creatine Gummy Using Cold-Processing Technology
03/02/2026
HONG KONG, China, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Natures Aid has introduced an NSF-certified creatine gummy designed to provide a convenient alternative to traditional creatine formats such as powders and capsules, [...]
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth disease (CMT) [...]

Pages